US industry convenes meeting on FDA's post-market safety progress:
This article was originally published in Clinica
Executive Summary
AdvaMed has scheduled a two-day meeting in Bethesda, next month, on the FDA's post-market safety activities. Association officials said the meeting is intended to be a follow-up to a meeting last September on post-market issues involving implantable cardioverter defibrillators and pacemakers. That meeting was organised by the Heart Rhythm Society in the wake of a series of high-profile ICD recalls that led to heightened scrutiny of the industry. The upcoming workshop is scheduled for February 8-9. "It will set the stage for collaboration process improvement initiatives," AdvaMed said, and will be the first in a series of joint post-market workshops with the agency.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.